Confirmation No.: 8229

512100-2046

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : HOFFMANN ET AL

Serial No. : 10/533,926

For : TRANSMUCOSAL PHARMACEUTICAL

**ADMINISTRATION FORM** 

Filed : MAY 4, 2005

Examiner : MICHAEL P. WOODWARD

Art Unit : 1615

745 Fifth Avenue New York, NY 10151

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed are copies of publications the subject matters of which are mentioned in the specification for the Examiner's review:

- 1. US 2004/0028732 A1, February 12, 2004, Falkenhausen et al.;
- 2. WO 00/07597 A1, published February 17, 2000;
- 3. WO 03/063839 A1, published August 7, 2003;
- 4. WO 01/12155 A1, published February 21, 2001;
- 5. DE 100 24 413 A1, published December 6, 2001;

-1- 00482740.DOC

Confirmation No.: 8229 512100-2046

- 6. Ohtsuka et al, "Dipalmitoylphosphatidylcholine (L-alpha-lecithin) stimulates phospholipase A2 activity in human amnion." <u>Biochem. Biophys. Res. Commun.</u>, 1990 Jul 16, 170(1): 328-35 (abstract only);
- 7. US 2003/0170194 A1, September 11, 2003, Piotrowiak et al.

The referenced United States Patent number 2004/0028732 A1 is submitted as the parallel U.S. Application of German Patent number DE 100 32 456 A1, cited as reference "AK" in PTO-1449 which was filed for this case on May 4, 2005. References 2 and 3 on this communication were cited in 2005 by the German Patent Office and are now being brought to the attention of the USPTO. References 4 through 6 were cited in Germany on February 21, 2007, and reference 7 is submitted as the parallel U.S. application of reference 5.

We have enclosed a copy of PTO-1449 in duplicate which is considered part of the Supplemental Information Disclosure Statement.

Pursuant to 37 CFR §1.98(2)(ii), no copies of U.S. patents or U.S. patent publications are enclosed. However, Applicants will provide a copy if required by the U.S. Patent and Trademark Office.

This Supplemental Information Disclosure Statement is being submitted prior to receipt of a first Office Action, so no fee is deemed necessary. However, if a fee is required, the Examiner is hereby authorized to charge our Deposit Account 50-0320.

Applicant respectfully requests that the Examiner consider and make of record the documents cited herein.

Applicant believes there is no fee involved with this procedure. However, if a fee is deemed necessary, please charge our Deposit Account No. 50-0320.

Confirmation No.: 8229

512100-2046

Respectfully submitted, FROMMER LAWRENCE & HAUG LLP

By:

Howard C. Lee
William F. Lawrence
Reg. No. 28,029

Howard C. Lee Reg. No. 48,104 (212) 588-0800